Detection of Human Anti-Trypanosoma cruzi Antibody with Recombinant Fragmented Ribosomal P Protein.
Detection of Human Anti-Trypanosoma cruzi Antibody with Recombinant Fragmented Ribosomal P Protein. Korean J Parasitol. 2019 Aug;57(4):435-437 Authors: Kim YH, Yang Z, Lee J, Ahn HJ, Chong CK, Maricondi W, Dias RF, Nam HW Abstract Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, and is endemic in many Latin American countries. Diagnosis is based on serologic testing and the WHO recommends two or more serological tests for confirmation. Acidic ribosomal P protein of T. cruzi showed strong reactivity against positive sera of patients, and we cloned the protein after fragmenting it to enhance its antigenicity and solubility. Twelve positive sera of Chagas disease patients were reacted with the fragmented ribosomal P protein using western blot. Detection rate and density for each fragment were determined. Fragments F1R1, F1R2, and F2R1 showed 100% rate of detection, and average density scoring of 2.00, 1.67, and 2.42 from a maximum of 3.0, respectively. Therefore, the F2R1 fragment of the ribosomal P protein of T. cruzi could be a promising antigen to use in the diagnosis of Chagas disease in endemic regions with high specificity and sensitivity. PMID: 31533412 [PubMed - in process]
Background: American trypanosomiasis or Chagas disease represents a major health problem and continues to be endemic in large areas of Latin America. The causal agent of this emergent parasitic infectious disease is Trypanosoma cruzi. At present, the amount of infected people worldwide projected the World Health Organization sums to 8 –10 million. T. cruzi contains a major antigen, cruzipain (Cz), with an unusual C-terminal extention (C-T), retained in the mature protein. C-T bears a number of post translational modifications and is responsible for the immunogenicity of the molecule.
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, is endemic to parts of Mexico and Central/South America. Chagas heart disease develops in 20-30% of patients; manifestations include conduction abnormalities (e.g. right bundle branch block [RBBB]), ventricular tachycardia (VT), and progressive dilated cardiomyopathy1. The estimated prevalence of CD in the US exceeds 300,000 people2, and CD accounts for ∼19% of non-ischemic cardiomyopathy3, 7.5% of pacemakers4, and 5% of conduction abnormalities5 among Latin American immigrants in California.
CONCLUSIONS The results reinforce the recommendation that these standards be considered for performance evaluations of commercialised immunoassays and should be an integral step in the development of new test components or assay paradigms. PMID: 32725060 [PubMed - as supplied by publisher]
CONCLUSION: These results suggest that the double or triple infection is a phenomenon existing in almost all the coendemics areas and mammals studied, which might influence the mechanisms of adaptation and pathogenicity of these parasites. PMID: 32655075 [PubMed - in process]
Chagas disease is an endemic chronic parasitosis in Latin America affecting more than 7 million people. Around 100 million people are currently at risk of acquiring the infection; however, no effective vaccine has been developed yet. Trypanosoma cruzi is the etiological agent of this parasitosis and as an intracellular protozoan it can reside within different tissues, mainly muscle cells, evading host immunity and allowing progression towards the chronic stage of the disease. Considering this intracellular parasitism triggers strong cellular immunity that, besides being necessary to limit infection, is not sufficient to er...
Chronic human infection by the protozoan parasite Trypanosoma cruzi, known as Chagas disease, results in heart failure and death in 20 to 30% of affected individuals. Recognition and treatment of the infection are difficult. Disease control requires elimination of the vector, the reduviid bug, that infests poor quality housing in endemic areas. In South America, control has largely succeeded in the Southern Cone countries — Argentina, Chile, Uruguay, Southern Brazil and São Paulo, and Paraguay — but lags severely in the Northern Triangle (Central American) countries: El Salvador, Honduras, and Guatemala.
Chronic human infection by the protozoan parasite Trypanosoma cruzi, known as Chagas disease, results in heart failure and death in 20%-30% of affected individuals. Recognition and treatment of the infection are difficult. Disease control requires elimination of the vector, the reduviid bug, that infests housing of poor quality in endemic areas. In South America, control has largely succeeded in the Southern Cone countries —Argentina, Chile, Uruguay, southern Brazil and São Paulo, and Paraguay—but lags severely in the Northern Triangle (Central American) countries: El Salvador, Honduras, and Guatemala.
The occurrence of the major vectors of Chagas disease has historically been linked to poor rural housing, but urban or peri-urban infestations are increasingly being reported. We evaluated a simple risk index ...
par I Abstract Chagas disease caused by the hemoflagelate parasite Trypanosoma cruzi is one of the most prevalent endemic parasitosis affecting 7-8 millions of people. Due to the complexity of the infection, no vaccines are available up to now. The extraordinary adjuvant capacity of BCG was explored in this work to develop a vaccine candidate to protect against Trypanosoma cruzi infection by using recombinant BCG vaccine platform. Three antigens of the parasite corresponding to an N and a C terminal fragments of the enzyme trans-sialidase (NT-TS and CT-TS respectively) and a fragment of the enzyme Cruzipain (CZf) ...
In conclusion, the high dispersion and colonization of T. dimidiata shown in this municipality, along the high rate of T. cruzi (TcI) infection and its anthropophilic behavior constitute a risk situation for Chagas disease transmission in this municipality certified without R. prolixus. The epidemiological implications of these findings are herein discussed. PMID: 32473116 [PubMed - as supplied by publisher]